Scienza e Tecnologia
Depixus Raises EUR 30.6M (USD 35.4M) in Series A Financing
-
PARIS and CAMBRIDGE, England , Dec. 15, 2021 /PRNewswire/ --
With MAGNA™, large numbers of individual molecules of DNA and RNA are captured in their native form, immobilised within a flow cell, and are then available for repeated interrogations that can reveal a broad range of features including base modifications, molecular structure, and interactions with other nucleic acids, proteins, or drugs. These capabilities unlock previously unattainable insights into the "dynamic genome" – the layers of information beyond the four-base coding sequences of DNA and RNA, that are key to gene expression, regulation, and control.
Detection of abnormal changes in base modification patterning have been shown to underpin many disease processes. The MAGNA™ technology will greatly accelerate access to this complex layer of the dynamic genome, opening up significant opportunities in the earlier detection and improved management of major diseases such as cancer. Moreover, the way in which nucleic acids, especially RNA, are folded and structured is also critical to biological regulation. With MAGNA™ these structures can often be revealed and analysed in detail. MAGNA™ therefore has strong potential as an aid in the discovery of drugs that either disrupt or stabilise RNA structures – affording opportunities to modulate hitherto 'undruggable' pathological cellular processes.
: " .
Following this capital raise, Lachlan MacKinnon and Thibaut Roulon , will join Mark Chin of Arix Bioscience, Ronald Lindsay , Steve Allen , Gordon Hamilton , and John Berriman , on the Board of Directors.
The company is based in Paris, France and Cambridge , UK, and is actively recruiting top talent to join its team.
Depixus recently announced the publication of a scientific paper showcasing the MAGNA capabilities in the peer-reviewed journal Communications Biology, part of Nature Research journals. The paper, entitled , can be freely downloaded here.
Depixus is a fast-growing innovative biotechnology company based in Paris, France , and Cambridge, UK , developing its cutting-edge MAGNA™ technology to reveal the secrets of the dynamic genome. The technology is set to transform our understanding of how genetics is regulated and provide powerful new insights into the mechanisms of disease.
Depixus is a spin-out from spin-out from Ecole Normale Supérieure (ENS), one of the most prestigious 'grandes écoles' in France . The company has been financed not only through equity investment but also via numerous grants, including from the EU's Horizon 2020 SME Instrument and Innovate UK programmes.
The MAGNA™ technology is based on an instrument system called a 'magnetic trap'. Samples of nucleic acid are captured within a flow cell and then can be analysed at multiple levels of resolution. To learn more about the way the MAGNA™ technology works and some of the many different assays that can be performed with the platform, please visit www.depixus.com.
Lansdowne Partners is an investment management partnership founded in 1998. The firm manages assets for a diversified client base that includes some of the world's largest and most sophisticated investors.
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export…).
Created in June 2017 as part of the Future Investment Program (PIA) and managed on behalf of the State by Bpifrance, the PSIM fund "Major Innovation Support Program" aims in particular to support the winners of the Global Innovation Competition via an equity investment. It enables French start-ups to move towards the industrialization of their breakthrough innovations and their international development.
For more information, please visit: https://www.bpifrance.com/
Follow us on Twitter: @Bpifrance - @BpifrancePresse